Morningstar Founder Joseph Mansueto Has Sold $1.95 Billion in MORN Stock — 7,250 Shares Every Trading Day
The man who built the world's leading fund-rating platform sells his own stock at a metronomic 7,250-share daily cadence. Career total: nearly $2 billion across 11,033 Form 4 transactions.
Joseph Mansueto founded Morningstar (MORN) in 1984 — the company that built its reputation rating other people’s investment decisions. His own investment decision? Sell exactly 7,250 shares every trading day, through price rallies and selloffs alike, with metronomic precision.
Career total: $1,953,910,056 in MORN sales across 11,033 Form 4 transactions. That is nearly $2 billion from the man who literally wrote the book on fund analysis.
The daily drip: 7,250 shares, every day
Mansueto’s November 2025 selling window reveals the machine-like cadence. On nearly every trading day from November 3 through November 21, the pattern held: sell approximately 7,250 shares, collect $1.5M, repeat.
| Date | Shares Sold | Avg Price | Day Value |
|---|---|---|---|
| Nov 3 | 7,250 | $211.95 | $1.54M |
| Nov 4 | 6,918 | $213.72 | $1.48M |
| Nov 5 | 7,250 | $211.03 | $1.53M |
| Nov 7 | 7,250 | $211.89 | $1.54M |
| Nov 10 | 7,250 | $215.18 | $1.56M |
| Nov 11 | 7,250 | $215.71 | $1.56M |
| Nov 12 | 7,250 | $215.03 | $1.56M |
| Nov 13 | 6,848 | $215.30 | $1.47M |
| Nov 14 | 6,969 | $213.32 | $1.49M |
| Nov 18 | 7,250 | $208.29 | $1.51M |
| Nov 19 | 7,250 | $209.26 | $1.52M |
| Nov 20 | 7,250 | $210.89 | $1.53M |
| Nov 21 | 7,250 | $211.22 | $1.53M |
Thirteen trading days, approximately 94,235 shares and $19.8 million in proceeds. Then in February 2026, the same cadence resumed at lower prices:
- Feb 17: 7,304 shares at $160.63 — $1.17M
- Feb 18: 6,737 shares at $159.09 — $1.07M
The price dropped 25% from November (~$212) to February (~$160). The selling cadence did not change.
Mansueto Daily MORN Sales — Nov 2025 Through Feb 2026
The irony of the ratings giant
Morningstar is the company that invented the five-star mutual fund rating system. Its analysts evaluate institutional investors, fund managers, and portfolio strategies for a living. When Morningstar’s own founder runs a textbook 10b5-1 daily drip program, it carries a particular weight.
To be clear, this is not a bearish signal. Mansueto is a founder who has been diversifying for years. His 10b5-1 plan is exactly the kind of systematic selling that Morningstar’s own governance research recommends. The cadence is the story — not the direction.
Position snapshot
| Metric | Value |
|---|---|
| Career Form 4 transactions | 11,033 |
| Career sell value | $1,953,910,056 |
| Career buy value | $0 |
| Daily sell cadence | ~7,250 shares |
| Shares remaining | ~8,190,000 |
| Est. remaining value | ~$1.3B (at $160) |
| Dec 2025 gift | 27,775 shares |
What to watch
- Whether the 7,250-share cadence continues through Q1 2026 — at current rates, Mansueto sells roughly 150,000 shares per month (~$24M at $160).
- The 25% price decline from November to February: if the cadence persists, monthly dollar proceeds shrink proportionally.
- MORN earnings and any forward guidance that could stabilize or further pressure the share price.
- Gift transactions (code G) like the December 27,775-share transfer — these reduce the share count without market impact.
Related Research
Explore all researchWEALTH ENHANCEMENT ADVISORY SERVICES, LLC reported 49.10B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Robeco filed a fresh 2026Q1 13F with $70.16B of reported value, led by Nvidia, Apple, Microsoft, Alphabet, and Amazon.
KEYBANK NATIONAL ASSOCIATION/OH reported 27.38B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Retirement Systems of Alabama reported 29.98B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Wasatch Advisors' 2026Q1 13F showed a $15.06B reported book led by HealthEquity, Ensign, Medpace and a set of small and mid-cap growth names.